Compare AMETEK, Inc. (AME) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMETEK, Inc. vs BioNano Genomics Inc — how do they compare? AMETEK, Inc. trades at $232.93 (market cap $53.63B), while BioNano Genomics Inc trades at $1.2 (market cap $13.77M). The key difference: AMETEK, Inc. is far larger — about 3894.7× BioNano Genomics Inc's market cap, and AMETEK, Inc. pays a 0.58% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AME | BNGO | |
|---|---|---|
Market Cap | $53.63B | $13.77M |
Sector | Industrials | Health |
52-Week High | $241.94 | $4.92 |
52-Week Low | $176.44 | $1.09 |
Enterprise Value | $55.33B | $16.38M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
BNGO trades at $1.20, up 5.26% today, but technical signals are bearish with moving averages indicating selling pressure. The company reported a net loss of -$26.40M in 2025 despite beating EPS estimates in recent quarters. Recent news highlights leadership changes and growing adoption of its optical genome mapping technology, with 67% year-over-year growth in studies presented at ESHG 2026 (GlobeNewswire, June 18, 2026).
The outlook remains challenged by persistent losses and negative cash flow, though low valuation ratios (P/S 0.31, P/B 0.37) may attract value investors. Analyst sentiment is cautiously optimistic with 57% buy ratings, but execution risks and profitability concerns pose significant headwinds for near-term stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
